{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cytotoxic+t-lymphocytes&page=4", "query": { "intervention": "cytotoxic t-lymphocytes", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 320, "total_pages": 32, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cytotoxic+t-lymphocytes&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cytotoxic+t-lymphocytes&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T21:52:51.084Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04887870", "title": "Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced or Metastatic Solid Malignancies" ], "interventions": [ { "name": "Sitravatinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Enfortumab Vedotin-Ejfv", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2021-06-29", "completion_date": "2025-09-25", "has_results": true, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-06T21:52:51.084Z", "location_count": 13, "location_summary": "Littleton, Colorado • Goshen, Indiana • Boston, Massachusetts + 10 more", "locations": [ { "city": "Littleton", "state": "Colorado" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04887870" }, { "nct_id": "NCT04013542", "title": "Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALK Gene Rearrangement", "EGFR Gene Mutation", "Locally Advanced Lung Non-Small Cell Carcinoma", "Lung Non-Small Cell Carcinoma", "Stage II Lung Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2019-09-13", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-06T21:52:51.084Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04013542" }, { "nct_id": "NCT01333046", "title": "Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin Lymphoma", "Non-Hodgkin Lymphoma", "Hodgkin Disease" ], "interventions": [ { "name": "Antigen-Escalation Stage", "type": "BIOLOGICAL" }, { "name": "Dose-Escalation Stage", "type": "BIOLOGICAL" }, { "name": "azacytidine and multiTAA T cells Stage", "type": "BIOLOGICAL" }, { "name": "Pediatric multiTAA T cells Stage", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2012-01", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-06T21:52:51.084Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01333046" }, { "nct_id": "NCT01769222", "title": "Ipilimumab and Local Radiation for Selected Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Colon Cancer", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Melanoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Rectal Cancer", "Recurrent Small Lymphocytic Lymphoma", "Refractory Hairy Cell Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2013-02", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2024-01-24", "last_synced_at": "2026-10-06T21:52:51.084Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01769222" }, { "nct_id": "NCT02530463", "title": "Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplastic Syndrome", "Recurrent Myelodysplastic Syndrome" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2015-09-08", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-06T21:52:51.084Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02530463" }, { "nct_id": "NCT05302921", "title": "Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteosarcoma", "Ewing Sarcoma", "Rhabdomyosarcoma", "Relapsed Pediatric Solid Tumor", "Refractory Pediatric Solid Tumor", "Melanoma", "Hepatoblastoma", "Hepatocellular Carcinoma", "Neuroblastoma", "Wilms Tumor" ], "interventions": [ { "name": "Cryoablation Therapy", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Children's National Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "39 Years", "sex": "ALL", "summary": "1 Year to 39 Years" }, "enrollment_count": 5, "start_date": "2022-02-18", "completion_date": "2024-03-12", "has_results": false, "last_update_posted_date": "2025-01-01", "last_synced_at": "2026-10-06T21:52:51.084Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05302921" }, { "nct_id": "NCT03116529", "title": "Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Combination Radiation, Immunotherapy, Surgery", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2017-06-21", "completion_date": "2024-06-21", "has_results": false, "last_update_posted_date": "2024-11-04", "last_synced_at": "2026-10-06T21:52:51.084Z", "location_count": 3, "location_summary": "Tucson, Arizona • Baltimore, Maryland • Pittsburgh, Pennsylvania", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03116529" }, { "nct_id": "NCT02498600", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2015-08-10", "completion_date": "2025-07-26", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-10-06T21:52:51.084Z", "location_count": 201, "location_summary": "Auburn, California • Berkeley, California • Cameron Park, California + 140 more", "locations": [ { "city": "Auburn", "state": "California" }, { "city": "Auburn", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Cameron Park", "state": "California" }, { "city": "Davis", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02498600" }, { "nct_id": "NCT00078533", "title": "Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cytomegalovirus Infections" ], "interventions": [ { "name": "CMV CTL infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 26, "start_date": "2004-04", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2014-10-08", "last_synced_at": "2026-10-06T21:52:51.084Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00078533" }, { "nct_id": "NCT02479698", "title": "Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "BK Virus Infection", "Human Immunodeficiency Virus", "JC Virus Infection", "Malignant Neoplasm", "Merkel Cell Carcinoma", "Merkel Cell Polyomavirus Infection", "Viral Encephalitis" ], "interventions": [ { "name": "Allogeneic BK-specific Cytotoxic T-lymphocytes", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 100, "start_date": "2015-07-23", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-06T21:52:51.084Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02479698" } ] }